Sign in
← Database
Oral Non-Peptide GLP-1 Agonist

Orforglipron

Shop · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

An investigational orally administered, non-peptide small-molecule agonist of the GLP-1 receptor developed by Eli Lilly and studied in late-stage trials for type 2 diabetes and obesity; not yet approved at the time of writing.

How it works

Orforglipron is an experimental medicine designed to activate the same receptor targeted by injectable drugs like semaglutide, the GLP-1 receptor, which is involved in blood sugar control and appetite. The key difference is that orforglipron is a small synthetic molecule taken as a pill rather than a peptide that must be injected. This oral, non-peptide design is what makes it notable, since most GLP-1 medicines to date have been injectable peptides.

By switching on the GLP-1 receptor, the compound is intended to enhance insulin release when blood sugar is high and to reduce appetite, which is why it has been investigated for both type 2 diabetes and obesity. Because it is a chemically stable small molecule, it does not require the refrigeration or food-timing constraints of some peptide therapies, and it has been studied in large late-stage clinical trials.

It is important to be clear that orforglipron is still investigational and not approved at the time of writing, so its full safety profile, long-term effects, and eventual labeling are not yet established. As with the broader GLP-1 class, gastrointestinal side effects such as nausea are a known consideration. This entry describes its mechanism and development status only and is not a treatment recommendation or dosing guide.

Mechanism · Detailed Analysis
Molecular targetOrforglipron is a non-peptide small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Unlike peptide incretin mimetics that engage the receptor's large extracellular domain, small-molecule agonists are thought to interact with the receptor in a distinct manner consistent with oral small-molecule pharmacology, producing receptor activation without a peptide backbone.
Signaling & downstream effectsAgonism at GLP-1R couples primarily through Gs to adenylate cyclase, raising intracellular cyclic AMP. In pancreatic beta cells this potentiates glucose-dependent insulin secretion, an action that is largely contingent on elevated glucose and therefore carries a low intrinsic hypoglycemia risk; central and peripheral GLP-1R signaling also promotes satiety and slows gastric emptying, the mechanisms underlying reduced food intake and weight effects studied in obesity trials.
PharmacokineticsAs an orally bioavailable small molecule rather than a peptide, orforglipron is not dependent on injection and is not subject to the proteolytic degradation that limits oral delivery of peptide GLP-1 agonists; its small-molecule nature has been described as compatible with once-daily oral dosing without the food and water administration constraints associated with the oral peptide semaglutide formulation. Specific exposure parameters are being characterized in clinical development and are not reproduced here.
CaveatsOrforglipron is investigational and not approved at the time of writing; its long-term efficacy, safety, and final regulatory status remain to be determined. Consistent with the GLP-1 receptor agonist class, gastrointestinal adverse effects such as nausea, vomiting, and diarrhea are anticipated tolerability considerations. No trial result figures, endpoints, or dosing are provided here; this entry is educational and not medical advice.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.